Prostate Cancer - Brazil Drug Forecast and Market Analysis to 2023


#841023

186pages

GlobalData

$ 4995

In Stock

Prostate Cancer - Brazil Drug Forecast and Market Analysis to 2023

Summary

Prostate cancer is the second most common cancer in men worldwide, after skin cancer. It accounts for 15% of all the cancers diagnosed in men, and thus represents a huge burden on healthcare systems. While patients diagnosed with early-stage, localized prostate cancer can be cured, patients who are diagnosed with or progress to castration-resistant prostate cancer (CRPC) have no curative options. This report focuses on the current treatment landscape, unmet needs, pipeline assessment and market outlook for prostate cancer. . Since 2010, five new drugs have been approved for the treatment of CRPC: Dendreons Provenge, Sanofis Jevtana, Johnson & Johnsons Zytiga, Medivation/Astellas Xtandi, and Bayers Xofigo. During the forecast period from 2013-2023, GlobalData expects that nine new late-stage pipeline agents will launch, eight of which will be for the treatment of CRPC. As a result of this unprecedented level of clinical development, GlobalData predicts there will be massive changes in the CRPC treatment paradigm. In addition, due to the influx of new therapies, the size of the prostate cancer market across the nine major pharmaceutical markets (9MM) (US, France, Germany, Italy, Spain, UK, Japan, Brazil, and Canada) will increase three-fold.

In 2013, GlobalData estimated that the sales of branded prostate cancer therapies in Brazil were $167m. This exceptionally strong growth will be a result of the increasing incidence of prostate cancer in Brazil as the population ages.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

- Overview of Prostate Cancer including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Brazil including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Brazil from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting Brazil Prostate Cancer market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Prostate Cancer.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2013-2023 in Brazil.
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 9
2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 11
2.3 Upcoming Related Reports 12
3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 13
3.2 Staging 14
3.3 Symptoms 18
3.4 Prognosis 18
3.5 Quality of Life 19
4 Disease Management 20
4.1 Diagnosis and Treatment Overview 20
4.1.1 Screening and Diagnosis 20
4.1.2 Treatment Guidelines and the Leading Prescribed Drugs 22
4.1.3 Clinical Practice 24
4.2 Brazil 34
5 Competitive Assessment 35
5.1 Overview 35
5.2 Product Profiles - Major Brands, Targeted Therapies 36
5.2.1 Zytiga (abiraterone acetate) 36
5.2.2 Xtandi (enzalutamide) 42
5.2.3 Xofigo (radium 223 dichloride) 47
5.3 Product Profiles - Major Brands, Chemotherapies 53
5.3.1 Jevtana (cabazitaxel) 53
5.4 Product Profiles - Major Brands, Therapeutic Vaccines 57
5.4.1 Provenge (sipuleucel-T) 57
5.5 Product Profiles - Major Brands, Hormone Therapies 61
5.5.1 Zoladex (goserelin acetate) 61
5.5.2 Lupron Depot (leuprolide acetate) 64
5.5.3 Eligard (leuprolide acetate) 67
5.5.4 Trelstar (triptorelin acetate) 69
5.5.5 Firmagon (degarelix) 71
5.5.6 Casodex (bicalutamide) 74
5.6 Product Profiles - Major Brands, Bone Therapies 77
5.6.1 Zometa (zoledronic acid) 77
5.6.2 Xgeva (denosumab) 79
6 Unmet Need and Opportunity 83
6.1 Overview 83
6.2 Therapies That Provide a Durable Overall Survival Benefit for mCRPC Patients 84
6.2.1 Unmet Need 84
6.2.2 Gap Analysis 85
6.2.3 Opportunity 86
6.3 Therapeutic Options for nmCRPC Patients 86
6.3.1 Unmet Need 86
6.3.2 Gap Analysis 87
6.3.3 Opportunity 87
6.4 Identification of Biomarkers to Predict Zytiga and Xtandi Resistance 88
6.4.1 Unmet Need 88
6.4.2 Gap Analysis 89
6.4.3 Opportunity 90
6.5 Defining the Best Sequence of Drugs to Manage mCRPC 90
6.5.1 Unmet Need 90
6.5.2 Gap Analysis 91
6.5.3 Opportunity 92
7 Pipeline Assessment 93
7.1 Overview 93
7.2 Product Profiles Immunotherapies 96
7.2.1 Yervoy (ipilimumab) 96
7.2.2 ProstVac 102
7.2.3 ProstAtak 107
7.2.4 DCVAC/PCa 112
7.2.5 ITK1 117
7.3 Product Profiles - Targeted Therapies 122
7.3.1 Custirsen Sodium 122
7.3.2 Tasquinimod 127
7.3.3 ARN-509 132
7.3.4 ODM-201 136
8 Market Outlook 142
8.1 Brazil 142
8.1.1 Forecast 142
8.1.2 Key Events 145
8.1.3 Drivers and Barriers 146
9 Appendix 147
9.1 Bibliography 147
9.2 Abbreviations 166
9.3 Methodology 171
9.4 Forecasting Methodology 171
9.4.1 Diagnosed Prostate Cancer Patients 171
9.4.2 Percentage Drug-Treated Patients 172
9.4.3 Drugs Included in Each Therapeutic Class 172
9.4.4 Launch and Patent Expiry Dates 173
9.4.5 General Pricing Assumptions 174
9.4.6 Individual Drug Assumptions 175
9.4.7 Pricing of Pipeline Agents 178
9.5 Primary Research - KOLs Interviewed for This Report 180
9.6 Primary Research - Prescriber Survey 182
9.7 About the Authors 183
9.7.1 Analyst 183
9.7.2 Director of Oncology 183
9.7.3 Epidemiologist 184
9.7.4 Global Head of Healthcare 184
9.8 About GlobalData 185
9.9 Disclaimer 185

1.1 List of Tables
Table 1: TNM Classification of Prostate Cancer 16
Table 2: Prostate Cancer Staging 17
Table 3: Risk-Group Classifications Used in Prostate Cancer 18
Table 4: Most Commonly Used Treatment Guidelines for Prostate Cancer, 2014 22
Table 5: Most Commonly Prescribed Hormonal Therapies for Prostate Cancer, 2014 23
Table 6: Most Commonly Prescribed Chemotherapeutic, Drug, and Bone Therapies for CRPC, 2014 24
Table 7: Diagnosis and Treatment of Prostate Cancer, Country Profile - Brazil 34
Table 8: Leading Branded Drugs Used to Treat Prostate Cancer, 2014 36
Table 9: Product Profile - Zytiga 38
Table 10: Zytiga SWOT Analysis, 2014 40
Table 11: Global Sales Forecasts ($m) for Zytiga, 20132023 41
Table 12: Product Profile - Xtandi 44
Table 13: Xtandi SWOT Analysis, 2014 46
Table 14: Global Sales Forecasts ($m) for Xtandi, 20132023 47
Table 15: Product Profile - Xofigo 50
Table 16: Xofigo SWOT Analysis, 2014 51
Table 17: Global Sales Forecasts ($m) for Xofigo, 20132023 52
Table 18: Product Profile - Jevtana 54
Table 19: Jevtana SWOT Analysis, 2014 55
Table 20: Global Sales Forecasts ($m) for Jevtana, 20132023 56
Table 21: Product Profile - Provenge 59
Table 22: Provenge SWOT Analysis, 2014 60
Table 23: Global Sales Forecasts ($m) for Provenge, 20132023 61
Table 24: Product Profile - Zoladex 62
Table 25: Zoladex SWOT Analysis, 2014 64
Table 26: Product Profile - Lupron 65
Table 27: Lupron SWOT Analysis, 2014 66
Table 28: Product Profile - Eligard 68
Table 29: Eligard SWOT Analysis, 2014 69
Table 30: Product Profile - Trelstar 70
Table 31: Trelstar SWOT Analysis, 2014 71
Table 32: Product Profile - Firmagon 72
Table 33: Firmagon SWOT Analysis, 2014 74
Table 34: Product Profile - Casodex 75
Table 35: Casodex SWOT Analysis, 2014 77
Table 36: Product Profile - Zometa 78
Table 37: Zometa SWOT Analysis, 2014 79
Table 38: Product Profile - Xgeva 81
Table 39: Xgeva SWOT Analysis, 2014 82
Table 40: Unmet Need and Opportunity in Prostate Cancer 84
Table 41: Drugs in Phase III Clinical Trials for Prostate Cancer 95
Table 42: Product Profile - Yervoy 98
Table 43: Yervoy SWOT Analysis, 2014 101
Table 44: Global Sales Forecasts ($m) for Yervoy, 20132023 102
Table 45: Product Profile - ProstVac 103
Table 46: ProstVac SWOT Analysis, 2014 106
Table 47: Global Sales Forecasts ($m) for ProstVac, 20132023 107
Table 48: Product Profile - ProstAtak 108
Table 49: ProstAtak SWOT Analysis, 2014 111
Table 50: Global Sales Forecasts ($m) for ProstAtak, 20132023 112
Table 51: Product Profile - DCVAC/PCa 113
Table 52: DCVAC/PCa SWOT Analysis, 2014 116
Table 53: Global Sales Forecasts ($m) for DCVAC, 20132023 117
Table 54: Product Profile - ITK1 118
Table 55: ITK1 SWOT Analysis, 2014 120
Table 56: Global Sales Forecasts ($m) for ITK1, 20132023 121
Table 57: Product Profile - Custirsen Sodium 123
Table 58: Custirsen Sodium SWOT Analysis, 2014 126
Table 59: Global Sales Forecasts ($m) for Custirsen Sodium, 20132023 127
Table 60: Product Profile - Tasquinimod 128
Table 61: Tasquinimod SWOT Analysis, 2014 131
Table 62: Global Sales Forecasts ($m) for Tasquinimod, 20132023 132
Table 63: Product Profile - ARN-509 133
Table 64: ARN-509 SWOT Analysis, 2014 135
Table 65: Global Sales Forecasts ($m) for ARN-509, 20132023 136
Table 66: Product Profile - ODM-201 137
Table 67: ODM-201 SWOT Analysis, 2014 140
Table 68: Global Sales Forecasts ($m) for ODM-201, 2013-2023 141
Table 69: Sales Forecasts ($m) for Prostate Cancer in Brazil, 20132023 143
Table 70: Key Events Impacting Sales for Prostate Cancer in Brazil, 2013-2023 145
Table 71: Brazil Prostate Cancer Market - Drivers and Barriers, 20132023 146
Table 72: Key Launch Dates, Marketed and Pipeline Prostate Cancer Drugs 173
Table 73: Key Patent Expiration or Loss of Market Exclusivity Dates, Marketed Prostate Cancer Drugs 173
Table 74: Average Body Weight and Surface Area Across the 9MM 175
Table 75: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country 182

1.2 List of Figures
Figure 1: Disease Management Flowchart for Prostate Cancer 25
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Prostate Cancer, 2013-2023 96
Figure 3: Yervoys Clinical Development 98
Figure 4: Potential Clinical and Commercial Positioning of Yervoy 100
Figure 5: ProstVacs Clinical Development 104
Figure 6: Potential Clinical and Commercial Positioning of ProstVac 105
Figure 7: ProstAtaks Clinical Development 109
Figure 8: Potential Clinical and Commercial Positioning of ProstAtak 110
Figure 9: DCVAC/PCas Clinical Development 113
Figure 10: Potential Clinical and Commercial Positioning of DCVAC/PCa 115
Figure 11: ITK1s Clinical Development 118
Figure 12: Potential Clinical and Commercial Positioning of ITK1 120
Figure 13: Custirsen Sodiums Clinical Development 124
Figure 14: Potential Clinical and Commercial Positioning of Custirsen Sodium 125
Figure 15: Tasquinimods Clinical Development 129
Figure 16: Potential Clinical and Commercial Positioning of Tasquinimod 130
Figure 17: ARN-509s Clinical Development 134
Figure 18: Potential Clinical and Commercial Positioning of ARN-509 135
Figure 19: ODM-201s Clinical Development 138
Figure 20: Potential Clinical and Commercial Positioning of ODM-201 139
Figure 21: Sales for Prostate Cancer in Brazil by Drug Class, 2013-2023 144